NEW YORK – SunRock Biopharma and Escugen on Tuesday said they've partnered to co-develop the antibody-drug conjugate (ADC) SRB123 as a treatment for solid tumors that overexpress CCR9. Escugen, ...

For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...

NEW YORK – OCCAM Immune, a research organization within Mount Sinai, announced a long-term partnership this week with the Cancer Research Institute to identify which cancer patients respond best to ...

In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...

The agency maintains that the beta-amyloid-targeting drugs show too limited benefit to justify their cost to the National Health Service.

Archeus hopes to begin a Phase I trial of the PSMA-targeted agent in metastatic, castration-resistant prostate cancer later this year.

NEW YORK – Singapore's Ministry of Health announced this week it will launch a genetic testing program to improve diagnosis of familial hypercholesterolemia (FH) as part of a broader national focus on ...

Studies doing genome-wide testing can easily ID patients with naturally low neutrophil counts, but nobody's looking at it, ...

The adaptive, biomarker-directed trial allows researchers to enrich for best responders and open new sub-studies for non-responders based on emerging data.

Trump administration health officials assured drugmakers and researchers at a roundtable hosted by the FDA that they want to ...